T. Rowe Price Investment Management Portfolio holdings
T. Rowe Price Investment Management, Inc. (TRPIM), a division of T. Rowe Price Group established in August 2022 and headquartered in Baltimore, Maryland, is an active investment manager overseeing hundreds of billions in assets, focusing on equity and fixed-income strategies for institutional clients and sub-advisory mandates. Spun off from the parent company founded in 1937 by Thomas Rowe Price, Jr., TRPIM operates as a distinct entity with around 900 employees, emphasizing a research-driven, long-term approach rooted in fundamental analysis and disciplined risk management. Managing portfolios like large-cap growth and international equity funds, it complements T. Rowe Price’s broader offerings while targeting sophisticated investors such as pension funds and endowments with tailored, high-conviction solutions. Under the leadership of president Rob Sharps, TRPIM upholds the firm’s legacy of integrity and client focus, adapting its founder’s value-oriented philosophy to modern institutional needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$874M |
| 2 |
Starbucks
SBUX
|
+$860M |
| 3 |
Becton Dickinson
BDX
|
+$660M |
| 4 |
NiSource
NI
|
+$655M |
| 5 |
Hilton Worldwide
HLT
|
+$624M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fortive
FTV
|
+$1.72B |
| 2 |
Marvell Technology
MRVL
|
+$1.06B |
| 3 |
Thermo Fisher Scientific
TMO
|
+$791M |
| 4 |
McKesson
MCK
|
+$738M |
| 5 |
WCN
Waste Connections
WCN
|
+$656M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.48% |
| 2 | Healthcare | 18.36% |
| 3 | Consumer Discretionary | 13.95% |
| 4 | Industrials | 10.53% |
| 5 | Financials | 9.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
651
Snap-on
SNA
$21.1B
| $417K | ﹤0.01% |
1,338
+211
| +19% | +$67.1K |
|
652
Accenture
ACN
$110B
| $408K | ﹤0.01% |
1,364
+444
| +48% | +$135K |
|
653
Paychex
PAYX
$42.8B
| $396K | ﹤0.01% |
2,717
+88
| +3% | +$13.2K |
|
654
Middleby
MIDD
$5.38B
| $317K | ﹤0.01% |
2,198
-329
| -13% | -$46.4K |
|
655
Iovance Biotherapeutics
IOVA
$3.05B
| $314K | ﹤0.01% |
182,436
-1,747,584
| -91% | -$4.35M |
|
656
CVS Health
CVS
$121B
| $178K | ﹤0.01% |
+2,568
| New | +$168K |
|
657
Edwards Lifesciences
EW
$53.6B
| $164K | ﹤0.01% |
+2,090
| New | +$156K |
|
658
Toro Company
TTC
$9.32B
| $162K | ﹤0.01% |
2,282
-30,160
| -93% | -$2.14M |
|
659
Regeneron Pharmaceuticals
REGN
$82.2B
| $152K | ﹤0.01% |
+288
| New | +$161K |
|
660
Bristol-Myers Squibb
BMY
$130B
| $145K | ﹤0.01% |
+3,113
| New | +$153K |
|
661
Vertex Pharmaceuticals
VRTX
$133B
| $133K | ﹤0.01% |
+297
| New | +$137K |
|
662
Sanofi
SNY
$105B
| $83K | ﹤0.01% |
+1,707
| New | +$87.2K |
|
663
AstraZeneca
AZN
$246B
| $64K | ﹤0.01% |
+457
| New | +$64K |
|
664
ICU Medical
ICUI
$4.48B
| $46K | ﹤0.01% |
+343
| New | +$46.5K |
|
665
Teva Pharmaceuticals
TEVA
$42.8B
| $39K | ﹤0.01% |
+2,299
| New | +$37.1K |
|
666
Enovis
ENOV
$1.42B
| $38K | ﹤0.01% |
1,202
-6,206,566
| -100% | -$205M |
|
|
ONC
667
BeOne Medicines Ltd
ONC
$40.6B
| $35K | ﹤0.01% |
+143
| New | +$35.1K |
|
668
Pfizer
PFE
$150B
| $33K | ﹤0.01% |
+1,354
| New | +$31.6K |
|
669
MoonLake Immunotherapeutics
MLTX
$1.47B
| $25K | ﹤0.01% |
+509
| New | +$20.7K |
|
670
Insulet
PODD
$10.1B
| $25K | ﹤0.01% |
+79
| New | +$22.8K |
|
671
Zai Lab
ZLAB
$2.86B
| $25K | ﹤0.01% |
+713
| New | +$23.4K |
|
672
DexCom
DXCM
$34.3B
| $22K | ﹤0.01% |
+243
| New | +$19K |
|
673
Apogee Therapeutics
APGE
$10.2B
| $21K | ﹤0.01% |
+464
| New | +$17.7K |
|
674
Moderna
MRNA
$25.4B
| $19K | ﹤0.01% |
+681
| New | +$17.9K |
|
|
ETNB
675
DELISTED
89bio
ETNB
| $10K | ﹤0.01% |
+974
| New | +$8.06K |
|
Similar funds
T. Rowe Price Investment Management's Q2 2025 Portfolio in Review
As of Q2 2025, T. Rowe Price Investment Management held 750 positions worth $158B, up 4.8% from $151B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
T. Rowe Price Investment Management's Q2 2025 filing shows 94 new, 316 increased, 272 reduced and 66 closed positions. Its largest new stake was Analog Devices: 1,692,080 shares worth $403M. The largest sale was Fortive, an estimated $1.72B.
By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Investment Management's largest Q2 2025 buy was Analog Devices: 1,692,080 shares worth $403M.
- T. Rowe Price Investment Management added most to Amazon in Q2 2025, an estimated $874M increase.
- T. Rowe Price Investment Management's biggest Q2 2025 reduction was Fortive, cutting an estimated $1.72B.
- T. Rowe Price Investment Management fully exited Marvell Technology in Q2 2025, selling an estimated $1.06B.
- T. Rowe Price Investment Management's ten largest holdings make up 21% of its $158B portfolio in Q2 2025.
- T. Rowe Price Investment Management opened 94 new positions and closed 66 in Q2 2025.
- T. Rowe Price Investment Management's portfolio value rose 4.8% quarter-over-quarter to $158B.
Based on T. Rowe Price Investment Management's 13F filing for Q2 2025, filed 14 Aug 2025.